Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model

Ian F. Harrison, Ozama Ismail, Asif Machhada, Niall Colgan, Yolanda Ohene, Payam Nahavandi, Zeshan Ahmed, Alice Fisher, Soraya Meftah, Tracey K. Murray, Ole P. Ottersen, Erlend A. Nagelhus, Michael J. O’Neill, Jack A. Wells and Mark F. Lythgoe

The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike.

1 UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK
2 Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK
3 School of Physics, National University of Ireland Galway, Ireland
4 Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK
5 Office of the President, Karolinska Institutet, Stockholm, Sweden
6 Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

Correspondence to: Ian F. Harrison
Centre for Advanced Biomedical Imaging, Paul O’Gorman Building
72 Huntley Street, University College London, London
WC1E 6DD, UK
E-mail: ian.harrison@ucl.ac.uk

Correspondence may also be addressed to: Mark F. Lythgoe
E-mail: m.lythgoe@ucl.ac.uk

Keywords: glymphatic; tau; aquaporin-4; Alzheimer’s disease; rTg4510
Abbreviation: ISF = interstitial fluid
Introduction

Impaired brain clearance mechanisms that result in the accumulation of aberrant proteins that define Alzheimer’s disease, provide new diagnostic and therapeutic opportunity to delay or prevent clinical symptoms. One such pathway for parenchymal protein clearance, the glymphatic system, has recently been described (Jessen et al., 2015). Its involvement in Alzheimer’s disease, however, is yet to be fully defined. Alzheimer’s disease is a devastating condition, neuropathologically characterized by the extracellular accumulation of amyloid-β in the form of plaques, and intracellular accumulation of hyperphosphorylated microtubule associated protein tau in the form of neurofibrillary tangles (NFTs). Blood–brain barrier clearance, intra- and extracellular degradation, interstitial fluid (ISF) bulk flow clearance and CSF absorption pathways have all been implicated in removal of parenchymal amyloid-β (Zlokovic et al., 2000; Glabe, 2001; Weller et al., 2008; Iliff et al., 2012; Hawkes et al., 2014), while tau is thought to be predominantly cleared by degradation, ISF bulk flow, and CSF absorption clearance mechanisms (Chesser et al., 2013; Iliff et al., 2014). Recent evidence, however, has suggested that the glymphatic system may contribute to a larger portion of parenchymal clearance of these protein species than previously thought (Iliff et al., 2012; Kress et al., 2014; Tarasoff-Conway et al., 2015).

The glymphatic clearance pathway was so named for its appropriation of the lymphatic function of interstitial protein management, and its dependence upon glial water transport (Jessen et al., 2015). Hence, it describes the exchange of para-arterial CSF with ISF in the parenchymal extracellular space, and para-venous clearance out of the brain (Iliff et al., 2012; Xie et al., 2013; Holter et al., 2017). Exchange of CSF with ISF is thought to be facilitated by the expression of aquaporin 4 (AQP4) channels on astrocytic endfeet; animals lacking AQP4 exhibit a ~70% reduction in CSF influx and a ~55% reduction in parenchymal solute clearance (Iliff et al., 2012; Mestre et al., 2018). Furthermore, deletion of AQP4 in APP/PS1 mice has been shown to potentiate the development of amyloid-β pathology and memory deficits (Xu et al., 2015), suggesting that suppressed glymphatic clearance is capable of inducing and/or advancing Alzheimer’s disease pathology. It has also been shown that the appropriate expression pattern of AQP4 polarization to astrocytic endfeet is required for efficient glymphatic CSF-ISF exchange (Iliff et al., 2014; Kress et al., 2014; Hadjihambi et al., 2019), and that this polarization in the brain declines with age (Kress et al., 2014; Zeppenfeld et al., 2016), the greatest risk factor for developing Alzheimer’s disease (Guerreiro and Bras, 2015). Moreover, it was shown recently that AQP4 polarization itself is associated with Alzheimer’s disease status (Zeppenfeld et al., 2016), suggesting that impaired glymphatic clearance may play a role in rendering the ageing brain vulnerable to aberrant protein deposition. Previous studies of glymphatic clearance in mouse models of Alzheimer’s disease however have focused largely on amyloid-β pathology (Peng et al., 2016). In human Alzheimer’s disease though, it is the tau burden, not amyloid-β load, that predicts both brain atrophy as well as cognitive status in patients with Alzheimer’s disease (Giannakopoulos et al., 2003). Furthermore, emerging evidence suggests that the extracellular space, which is cleared by the glymphatic system, acts as a conduit for neuron-to-neuron propagation and regional progression of Alzheimer’s disease tau pathology (Chesser et al., 2013; Ahmed et al., 2014; Medina and Avila, 2014; Lewis and Dickson, 2016; Wu et al., 2016). This raises the intriguing possibility that reduced glymphatic clearance of tau may potentiate disease progression via exacerbated neuron-to-neuron propagation of tangle susceptible tau protein, and as such, would be a powerful target for therapy.

Here we study the glymphatic system using MRI, the clearance of parenchymal tau using intracerebral injections and CSF sampling, and the modulation of AQP4 function, in a mouse model that develops tau NFT pathology (Ramsden et al., 2005) similar to that seen in neurodegenerative diseases such as Alzheimer’s disease (Braak and Braak, 1995). By using contrast-enhanced MRI, we provide a spatial and temporal description of the glymphatic system in the mouse brain, highlighting the heterogeneous nature of glymphatic inflow in the cortex, alluding to the critical role of this clearance system in the deposition of tau protein in the brain. We assess the function of glymphatic clearance in rTg4510 mice and their ability to clear parenchymal tau protein, as well as the expression pattern of AQP4 in affected regions. Finally, we demonstrate the critical role of this water channel, by pharmacologically inhibiting its function, and assessing the impact of such an inhibition on CSF-ISF exchange and tau clearance. In this study we provide the first demonstration of impaired glymphatic function in an animal model of tauopathy and establish the essential role of AQP4 in the clearance of tau protein from the brain.

Materials and methods

Animals and drugs

Generation of homozygous rTg4510 transgenic mice has been described previously (Ramsden et al., 2005). The rTg4510 and litter matched wild-type mice were licensed from the Mayo Clinic (Jacksonville, Florida, USA), bred for Eli Lilly by Taconic, and imported into the UK for study at UCL’s Centre for Advanced Biomedical Imaging. For TGN-020 experiments, C57BL/6 mice were used, imported from Charles River. For additional TGN-020 experiments, where stated, AQP4 knockout mice, generation of which has been described previously (Thrane et al., 2011) (henceforth referred to as Aqp4−/− mice) were used, imported directly from University of Oslo, Norway, into the UK for study at UCL’s Centre for Advanced Biomedical Imaging. In all other experiments, unless stated otherwise, female mice of 8.5 months of age were used. Animals were housed in groups of three to five in individually ventilated cages with ad libitum access to standard mouse chow pellets, drinking water, and environmental enrichment, on a 12-h light/dark...
cycle. All animal work was performed in accordance with the UK’s Animals (Scientific Procedures) Act of 1986 and was previously approved by UCL’s internal Animal Welfare and Ethical Review Body.

For pharmacological inhibition of AQP4, TGN-020 (N,1,3,4-thiadiazol-2-yl-3-pyridinecarboxamide) (Tocris Bioscience) was used (Huber et al., 2009). To increase solubility, TGN-020 was dissolved in a cyclodextrin derivative, 20% w/v Captisol® (CyDex Pharmaceuticals) in water for injection. For TGN-020 experiments, mice were treated intraperitoneally with either TGN-020 (250 mg/kg in 20 ml/kg body weight) or vehicle (empty 20% Captisol®; 20 ml/kg).

**Tau immunohistochemistry**

Immunohistochemistry was performed in order to quantify cortical deposition of tau in young rTg4510 mice. Female rTg4510 mice from 3.2 to 4.7 months of age were examined. Mice were perfused with PBS before removing and hemisecting the brain. The right hemisphere was drop fixed in 10% buffered formalin before being processed using the Tissue Tek VIP processor (GMI Inc) and embedded in paraffin wax. Sections (6 μm) of the brain in the sagittal plane were collected using a rotary microtome and mounted on glass slides. Following deparaffinization and rehydration of the tissue sections, antigen retrieval was carried out using the Lab Vision PT module system (Thermo Scientific), where sections were heated to 100°C for 20 min in citrate buffer (TA-250-PM1X; Thermo Scientific). Slides were transferred to a Lab Vision Autostainer (Thermo Scientific) where the following incubations were performed: 10 min in H2O2 (0.3%); 30 min in normal goat serum (1:20; Vector Laboratories); 60 min in primary antibody for tau phosphorylated at serine 409 (PG-5; 1:8000 from Peter Davies, Albert Einstein College of Medicine, NY, USA); 30 min in biotinylated goat anti-mouse IgG (1:200, BA9200; Vector Laboratories); 30 min avidin-biotin complex solution (PK-7100; Vector Laboratories); and 5 min in 3,3’-diaminobenzidine (SK-4105; Vector Laboratories). Apart from the last two steps, PBS with 0.05% Tween-20 (PBS-T) was used for diluting reagents and washes between steps. Sections were then counterstained with haematoxylin before dehydration and coverslipping. To quantify PG-5-positive tau pathology, stained sections were digitized using the Scanscope AT slide scanner (Aperio) at 20× magnification. Imagescope software (version 11.1.2.780; Aperio) was used to view the digitized tissue sections and delineate boundaries of the rostral and caudal cortex, and somatomotor and visual cortex areas. PG-5 immunoreactivity was quantified using the positive pixel algorithm (Imagescope, version 11.1.2.780; Aperio), and performed in a blinded fashion. Data are expressed as the ratio of percentage coverage of the total delineated boundary for rostral: caudal cortex, and somatomotor: visual cortex.

**Dynamic contrast-enhanced MRI**

**Surgical preparation**

Mice were anaesthetized with 2% isoflurane delivered in O2 at a delivery rate of 1 l/min, and positioned in a stereotaxic frame with the head flexed to 50°. A midline incision was made at a midpoint between the skull base and the occipital margin to the first vertebral. The underlying muscles were parted to expose the atlanto-occipital membrane and dura mater overlaying the cisterna magna, and a durotomy was performed using a 23-gauge needle. An intrathecal catheter (35–40 mm port length, 80–90 mm intravascular tippet length, Sandown Scientific) extended with polyethylene tubing (0.4 mm × 0.8 mm, Portex) and attached to a 50 μl glass Hamilton syringe driven by a microinfusion pump (sp210iw syringe pump, World Precision Instruments) was filled with low molecular weight paramagnetic contrast agent Magnevist® (21 mM Gd-DTPA, molecular weight 938 Da; Schering Health Care Ltd, in filtered 0.9% NaCl). The catheter was advanced 1 mm into the cisternal space, sealed and anchored in place using superglue and fast-setting resin (Araldite®).

**MRI acquisition**

Following surgery, animals were transferred to an MRI-compatible cradle with head held prone and a snout mask positioned to deliver 1.5% isoflurane in O2 at a delivery rate of 1 l/min. Core temperature and respiratory rate were monitored using a rectal probe and pressure pad, respectively (SA Instruments). Mice were maintained at 37°C (±2°C) using heated water tubing and a feedback loop controlled warm air blower (SA Instruments). Respiration rate was maintained between 80 and 120 breaths per minute by incrementally adjusting isoflurane dose. All imaging was performed with a 9.4 T VNMRS horizontal bore MRI scanner (Agilent Inc). A 72-mm inner diameter volume coil (Rapid Biomedical) was used for RF transmission and signal was received using a two-channel array head coil (Rapid Biomedical). A 3D T1-weighted gradient echo sequence was used to detect the motion of the Gd-DTPA with parameters: repetition time = 15 ms, echo time = 3.4 ms, flip angle = 15°, number of acquisitions = 3, field of view = 1.28 × 1.28 × 1.92 cm, scanning time = 12 min, acquisition matrix size of 128 × 128 × 128, yielding an image resolution of 0.1 × 0.1 × 0.15 mm. Three baseline scans were acquired prior to intrathecal infusion of Gd-DTPA via the indwelling catheter (30 μl at 0.6 μl/min, total time 50 min). Magnetic resonance images were continually acquired throughout and after intrathecal infusion for a total time of 180 min. At the end of the experiment the animal was euthanized by overdose with sodium pentobarbital (10 ml/kg, i.p.).

**Image processing and analysis**

First, the acquired T1-weighted MRI images were converted to the 3D NIfTI image format. Second, scan-to-scan misregistration caused by head movement was corrected by rigid-body alignment of each scan to the baseline averaged volume. Third, image intensity was normalized over the time series by estimating the intensity non-uniformity in the baseline volume and correcting all the volumes in the time series using the baseline intensity non-uniformity map, followed by 0.1 mm full-width at half-maximum isotropic Gaussian voxel-wise image intensity smoothing. For presentation of images, a difference image was calculated for each time point using the following expression:

\[
D(i, j, k) = |I(i, j, k) - B(i, j, k)|
\]

where \( D \) is the difference image, \( I \) is the time series image post Gd-DTPA infusion, \( B \) is the average baseline image, and \((i, j, k)\) represents the voxel position. Signal intensity measured on the T1-weighted magnetic resonance images over time in preselected anatomical areas were used to obtain intensity measurements.
Both the T1-weighted averaged baseline images and the contrast-enhanced T1-weighted magnetic resonance images were used to anatomically guide placement of 3D regions of interests. The intensity signal for each region of interest on each time-point image was extracted and expressed as a % change from the average baseline image. For calculation of kinetic parameters such as the maximal intensity and the time at which half maximal intensity was achieved in each brain region, group signal intensity versus time data were fitted to a sigmoidal model:

\[
y = \frac{\text{Intensity}_{\text{Max}}}{1 + e^{\left(\frac{\text{Time}_{50} - x}{\text{Slope}}\right)}}
\]

where \(\text{Intensity}_{\text{Max}}\) is the maximal intensity achieved in the brain region, \(\text{Time}_{50}\) is the time at which half maximal intensity is achieved, and \(\text{Slope}\) is the gradient of the linear portion of the fitted sigmoidal curve. Additionally, each region of interest \(\text{Intensity}_{\text{Max}}\) value was divided by its corresponding \(\text{Time}_{50}\) value to give a measure of ‘Penetration Efficiency’ for each brain region. The value of each of these parameters was extracted from the best-fit curve of each group dataset, and are presented with their associated 95% confidence interval (CI).

**Intracerebral infusion of tau and quantification of parenchyma-CSF tau clearance**

**Preparation and characterization of tau-containing brain homogenate**

Tau for intracortical injection was prepared by euthanizing an aged rTg4510 mouse (12 months of age) by overdose with sodium pentobarbital (10 ml/kg, i.p.) and dissecting out the cortex and hippocampus. Tissue was quickly frozen in isopentane on dry ice for storage at –80°C. Frozen tissue was weighed, thawed, and gently mixed in a mortar with a few strokes of a pestle in 10% w/v volumes of cold Tris-buffered saline (TBS) containing protease inhibitor cocktail, phosphatase inhibitor cocktails I and II (Sigma), at a final dilution of 1:100, and 1 mM phenylmethylsulphonyl fluoride. The resultant homogenate was centrifuged at 3000 rpm at 4°C for 5 min, and the pellet discarded. The supernatant was stored at –80°C until further analysis by ELISA. Water (2 µl) was added to the blood pellet and snap-frozen on dry ice to ensure hypotonic freeze-thaw release of haemoglobin from any red blood cells present. The same sample preparation was performed on a volume (approximately equal to the volume of CSF extracted from each animal) of whole blood. Each thawed sample was measured at 417 nm on a NanoDrop ND-1000 spectrophotometer (Thermo Fischer Scientific) to quantify percentage contamination of each CSF sample. This method allows for measurement of blood contamination down to 0.0001%, well below that detectable by eye (~0.01%). Lack of significant blood contamination was verified by an average percentage contamination of 0.003% (±0.0006%).

**Intracerebral infusion**

Mice were anaesthetized with 2% isoflurane delivered in O₂ at a delivery rate of 1 l/min, and positioned in a stereotaxic frame in the horizontal skull position. A midline incision was made on the top of the head to expose the underlying skull. A small burr hole was made, using a microdrill, above the location of the intracerebral injection. Tau (50 ng) containing brain homogenate (see above for preparation) was infused into either the rostral (anteroposterior, +2 mm, and mediolateral, +2 mm relative to bregma, and ventrodorsal, −0.75 mm, relative to the brain surface) (Paxinos and Franklin, 2013) or caudal (anteroposterior, −2 mm, and mediolateral, +2 mm relative to bregma, and ventrodorsal, −0.75 mm, relative to the brain surface) (Paxinos and Franklin, 2013) cortex, or the striatum (anteroposterior, −0.2 mm, and mediolateral, +2 mm relative to bregma, and ventrodorsal, −1.75 mm, relative to the brain surface) (Paxinos and Franklin, 2013) using a 10 µl glass Hamilton syringe (2.5 µl at 0.5 µl/min, total time 5 min). Either 15, 30, or 60 min after the start of the intracerebral infusion, with the needle left in situ, a midline incision was made at a midpoint between the skull base and the occipital margin to the first vertebrae. The underlying muscles were parted to expose the atlanto-occipital membrane and dura mater overlaying the cisterna magna, which was thoroughly cleaned with saline. A durotomy was performed using a 23-gauge needle, allowing CSF to be collected using a narrow bore pipette tip. Volume of CSF collected varied between genotype: 5–8 µl was routinely collected from wild-type mice, whereas 10–15 µl was routinely collected from rTg4510 mice. At the end of the experiment the animal was euthanized by overdose with sodium pentobarbital (10 ml/kg, i.p.).

**Confirmation of lack of blood contamination of CSF samples**

The collected CSF was centrifuged briefly to pellet any red blood cell contaminants. The supernatant was removed and frozen at −20°C until further analysis by ELISA. Water (2 µl) was added to the blood pellet and snap-frozen on dry ice to ensure hypotonic freeze-thaw release of haemoglobin from any red blood cells present. The same sample preparation was performed on a volume (approximately equal to the volume of CSF extracted from each animal) of whole blood. Each thawed sample was measured at 417 nm on a NanoDrop ND-1000 spectrophotometer (Thermo Fischer Scientific) to quantify percentage contamination of each CSF sample. This method allows for measurement of blood contamination down to 0.0001%, well below that detectable by eye (~0.01%). Lack of significant blood contamination was verified by an average percentage contamination of 0.003% (±0.0006%).

**Tau ELISAs**

Concentration of human tau in CSF samples was quantified using ELISAs. CSF total tau was quantified using Human Tau (total) ELISA Kit (#KHB0041, Invitrogen), and CSF phosphorylated tau was quantified using Human Tau (Phospho) (pS199) ELISA Kit (#KHB7041, Invitrogen), as per the manufacturer’s instructions. Briefly, CSF samples were diluted in diluent buffer prior to being incubated in capture antibody-coated wells for 2 h at room temperature. Wells were washed several times before being incubated in detection antibody-coated wells for 1 h at room temperature. Wells were washed again before being incubated with horseradish peroxidase conjugated secondary antibody for 30 min at room temperature. Wells were then washed again before being incubated with stabilized chromogen for 30 min at room temperature. After this incubation, stop solution was added to each well and the plate was read at 450 nm. A set of standards of known (p)Tau concentration [0, 31.25, 62.5, 125, 250, 500,
1000, 2000 pg/ml for total tau, and 0, 15.625, 31.25, 62.5, 125, 250, 500, 1000 pg/ml for phospho (pS199) tau, were run in parallel for each experiment for quantification of CSF sample tau content from the standard curve.

GFAP and AQP4 expression

**Messenger RNA expression**

For quantification of Gfap and Aqp4 mRNA expression in regions of interest, mice were euthanized by overdose with sodium pentobarbital (10 ml/kg, i.p.), the brain rapidly removed and snap-frozen in isopentane pre-chilled on dry ice. Sagittal sections (25 µm) of the brain were collected onto RNase-free SuperFrost Plus slides, using a cryostat. Brain tissue from regions of interest or total whole brain tissue were isolated from five sagittal sections (~1.0, 1.5, 2.0, 2.5 and 3.0 mm lateral to the midline (Paxinos and Franklin, 2013)) using a PALM MicroBeam laser capture microdissection system (Zeiss). Samples for each brain region for each animal were pooled and total RNA extracted using the RNeasy Plus Microkit (Qiagen) as per the manufacturer’s instructions. Total RNA was converted to cDNA using the QuantiTect Reverse Transcription Kit (Qiagen), which was then quantified using Eppendorf Mastercycler with Realplex software (v1.5, Eppendorf) and the TaqMan Gene Expression master mix (Applied Biosystems). TaqMan Gene Expression assays for each gene of interest (Gfap and Aqp4) and reference genes (Actb (β-actin) and Gapdh) were used, and gene expression of genes of interest determined using the 2–∆∆Ct method normalizing to expression in the wild-type whole brain.

**Protein expression**

For quantification of GFAP and AQP4 protein expression in regions of interest, mice were perfused with PBS before removing and hemisecting the brain. The right hemisphere was dropped fixed in 10% buffered formalin before being processed using the tissue TEK VIP processor (GMI Inc.) and embedded in paraffin wax. Sections (6-µm thick) of the brain in the sagittal plane were collected using a rotary microtome and mounted on glass slides. The following primary antibodies were used for immunohistochemistry: rabbit monoclonal GFAP (1:3000; PU020-UP, Biogenex) and mouse monoclonal AQP4 (1:200; ab9512, Abcam). In brief, tissue sections were deparaffinized and antigen retrieval, tissue sections were incubated in a cocktail of primary antibodies overnight at 4°C (CD31, 1:25 (ab28364, Abcam); GFAP (1:3000; PU020-UP, Biogenex); AQP4, 1:60 (ab9512, Abcam)), washed in PBS-T and then incubated in a cocktail of fluorophore-conjugated goat anti-rabbit (Alexa Fluor 488, 1:500; A11008) and goat anti-mouse (Alexa Fluor 568, 1:500; A11004) secondary antibodies (Invitrogen) for 2 h at room temperature. Finally, sections were washed in PBS-T and then dH2O, before being cover-slipped in VECTASHIELD mounting medium with DAPI (H-1200, Vector Labs). All incubations were performed manually and in a humidity tray, with minimal exposure to light. Immunofluorescence images were taken using a Leica DMLB fluorescent microscope and Q Capture Pro7 software (QImaging). Images were acquired by single excitation of each wavelength (separately) and channels subsequently merged.

Cellular localization of AQP4

**Immunofluorescence**

Tissue sections for subcellular localization of AQP4 in relation to cerebral blood vessels or astrocytes were processed as above and immunofluorescently stained for AQP4 (1:60, ab9512, Abcam), and either the blood vessel endothelial cell marker CD31 (1:25, ab28364, Abcam), or astrocyte marker GFAP (1:3000; PU020-UP, Biogenex). Following deparaffinization and antigen retrieval, tissue sections were incubated in a cocktail of primary antibodies overnight at 4°C (CD31, 1:25 (ab28364, Abcam); GFAP (1:3000; PU020-UP, Biogenex); AQP4, 1:60 (ab9512, Abcam), washed in PBS-T and then incubated in a cocktail of fluorophore-conjugated goat anti-rabbit (Alexa Fluor 488, 1:500; A11008) and goat anti-mouse (Alexa Fluor 568, 1:500; A11004) secondary antibodies (Invitrogen) for 2 h at room temperature. Finally, sections were washed in PBS-T and then dH2O, before being cover-slipped in VECTASHIELD mounting medium with DAPI (H-1200, Vector Labs). All incubations were performed manually and in a humidity tray, with minimal exposure to light. Immunofluorescence images were taken using a Leica DMLB fluorescent microscope and Q Capture Pro7 software (QImaging). Images were acquired by single excitation of each wavelength (separately) and channels subsequently merged.

**Quantification of AQP4 expression across blood vessel cross-sections**

Evaluation of the localization of AQP4 to perivascular endfeet and glial limits was carried out by measuring the pixel intensities of CD31 and AQP4 immunoreactivity across cross-sections of blood vessels in each of the brain regions studied. For this, vessel containing regions of interest were identified on DAPI images: identified using flattened nuclei, clusters or lines of nuclei out of focus compared to the surrounding tissue and ‘negative’ space between nuclei without background fluorescence. Fluorescent intensity for both CD31 and AQP4 markers were measured across a single 4 µm axis perpendicular to the vessel orientation, and expressed as intensity, normalized to the intensity of a randomly selected background region of interest in the same image for each antigen, to generate linear plots of fluorescence extending from the brain tissue, into the vessel and again into the surrounding brain tissue.

**Quantification of AQP4 polarization**

Perivascular polarization of AQP4 was measured as previously described (Kress et al., 2014). Briefly, the median immunofluorescence intensity of perivascular regions was measured. A threshold analysis was then used to measure the percentage of the region exhibiting AQP4 immunofluorescence greater than or equal to perivascular AQP4 immunofluorescence (AQP4% area). Polarization was expressed as the percentage of the region that exhibited lower AQP4 immunoreactivity than the perivascular endfeet. AQP4 vessel coverage was measured by firstly delimiting the area of the vessel from the CD31 channel image. This region of interest was then placed on the AQP4 channel.
image thresholded for immunoreactivity for extraction of the percentage vessel coverage (% immunoreactivity of AQP4 of whole delineated vessel).

**Statistical analysis**

Parameters extracted from sigmoidal fitting of MRI datasets are presented as best-fit values, with their associated 95% CI. All other data are represented as mean ± standard error of the mean (SEM) for the n number of animals in each group. Statistical comparisons between groups were performed via either a repeated measures two-way ANOVA followed by post hoc Bonferroni post-tests for multiple comparisons (for MRI data and immunofluorescence line profile data), or a regular two-way ANOVA followed by post hoc Bonferroni post-tests for multiple comparisons (for all other grouped comparisons not containing repeated measures). A one-way ANOVA was used for regional comparisons, and unpaired t-tests used for single comparisons. All statistical testing was performed using GraphPad Prism (v5 for Windows, San Diego, CA, USA).

**Data availability**

Raw data and images are available upon request from the corresponding author.

**Results**

**Heterogeneous deposition of tau in the cortex of the rTg4510 mouse**

Transgene expression in the rTg4510 mouse model is driven by the CaMK2a promoter and hence is restricted to the forebrain during the early stages of tau deposition. CaMK2a expression is notably homogenous throughout the cortex in the mouse brain (Fig. 1B) and hence the deposition of tau protein is hypothesized to be the same. PG-5 (Tau pS409) immunohistochemical analysis of 3.2 to 4.7-month-old rTg4510 mice, however, revealed greater rostral compared to caudal cortical tau pathology during early tau deposition in this model [rostral cortex PG-% immunoreactivity 5.98% (±0.67%) versus 3.03% (±0.49%) in the caudal cortex, in 3.2-month-old rTg4510 mice, rostral; caudal cortex PG-% immunoreactivity ratio, 2.15 (±0.44)] (Fig. 1C-F). Moreover when the ratio of rostral/caudal PG-5 immunoreactivity in extreme rostral/caudal aspects of the cortex is compared, i.e. the somatomotor versus visual cortex, the pattern of elevated rostral compared to caudal tau deposition becomes more apparent [somatomotor: visual cortex PG-% immunoreactivity ratio at 3.2 months, 2.83 (±0.50)] (Fig. 1F). This phenomenon, however, appears to subside with age, as mature NFT pathology takes hold [rostral/caudal cortex PG-% immunoreactivity ratio at 3.2 months, 2.15 (±0.44), compared to 1.22 (±0.15) at 4.7 months] (Fig. 1F). These data may indicate greater clearance of expressed phosphorylated tau in caudal compared to rostral aspects of the mouse cortex.

**Spatial and temporal profile of CSF-ISF exchange in the mouse brain**

To investigate whether cortical heterogeneity of glymphatic CSF-ISF exchange could be related to the findings in Fig. 1, we analysed regional glymphatic inflow in the healthy wild-type mouse. By investigating the wild-type brain in this way, rather than the rTg4510 brain, we sought to investigate whether regional heterogeneity of CSF-ISF exchange in the healthy brain may predispose certain regions to aberrant protein accumulation. The function of the glymphatic pathway was investigated by quantifying the regional delivery pattern of a magnetic resonance contrast agent (Gd-DTPA, Magnevist®) into the brain from the CSF compartment, via contrast-enhanced MRI. As such Gd-DTPA was infused...
intrathecally (via the cisterna magna) and T1-weighted images serially acquired over 3 h (Supplementary Fig. 1A). This demonstrated a distinct pattern of CSF flow into the mouse brain, confirming the distribution of glymphatic flow previously observed in rodents (Supplementary Fig. 1B–D) (Iliﬀ et al., 2013a; Gaberel et al., 2014). We observed a plateau in maximal MRI signal in all areas of the brain by ~90 min post-initiation of intrathecal Gd-DTPA infusion (Supplementary Fig. 1D). Time50 values, the time at which half-maximal intensity was observed, indicated that the superficial brain regions examined exhibit a distinct chronological sequence of Gd-DTPA inﬁltration (Supplementary Fig. 1D and F). T1 contrast was initially observed in the CSF ﬁlled aqueduct, progressing to ventral nuclei (the pontine nucleus and pituitary recess) and the caudal cortex. Later time points showed advancement of the signal throughout the brain, in the pineal recess and cerebellum, and more rostral regions, such as the rostral cortex and the olfactory bulbs.

Quantification of magnetic resonance signal in grey matter revealed heterogeneity of CSF-ISF exchange in the mouse brain (Fig. 2A–C). Consistent with the pattern of tau deposition in the cortex of tauopathy mice (Fig. 1), the rostral cortex of wild-type animals exhibited a relatively low level of Gd-DTPA inﬁltration [IntensityMax (% change from baseline), 7.44% (95% CI, 5.76 to 9.11%)]. Yet the caudal cortex exhibited a high level of contrast agent inﬁltration [IntensityMax (% change from baseline), 60.2% (95% CI, 57.8 to 62.6%)] (Fig. 2A and B). Moreover, MRI Gd-DTPA penetration eﬃciency [IntensityMax/Time50] demonstrated the heterogeneity of glymphatic CSF-ISF exchange in the cortex of wild-type animals even further [penetration eﬃciency in the caudal cortex, 1.51 (95% CI, 1.32 to 1.72), versus 0.10 (95% CI, 0.05 to 0.14) in the rostral cortex, P < 0.0001] (Fig. 2C).

To investigate this heterogeneity further, tau containing brain homogenate was infused into either the rostral or caudal cortex prior to CSF tau sampling from the cisterna magna (Fig. 2D). We observed a similar pattern to that observed with MRI, in that more parenchymal tau was cleared into CSF from the caudal compared to the rostral cortex [CSF tau post infusion into the rostral and caudal cortex, 0.98 ng/ml (±0.18 ng/ml) and 3.80 ng/ml (±0.22 ng/ml) respectively, P < 0.0001] (Fig. 2E).

Together these data suggest that glymphatic inﬂow in the wild-type mouse cortex, as quantiﬁed through contrast-enhanced MRI, corresponds well with the extent of parenchymal tau clearance, and that this is lower in the rostral compared to the caudal cortex, consistent with localization of early cortical tau deposition in transgenic tau animals.

Altered CSF-ISF exchange in the rTg4510 mouse

To ascertain the function of the glymphatic clearance system in the scenario of mature tauopathy and neurodegeneration, cisternal delivery of Gd-DTPA and serial T1-weighted MRI acquisition was performed in rTg4510 animals (8.5 months of age) (Fig. 3A and B). At this age, signiﬁcant mature NFT pathology is evident in the forebrain and is accompanied by neurodegeneration and cerebral atrophy (Ramsden et al., 2005; Spires et al., 2006; Holmes et al., 2016). We observed notable impaired CSF-ISF exchange in the caudal cortex of transgenic tau mice, as indicated by a signiﬁcant reduction of contrast agent penetration [Fig. 3C(i)], and reduced IntensityMax and increased Time50 values (Table 1) in this region.

In areas affected by tau pathology in the rTg4510 other than the caudal cortex, i.e. the rostral cortex and hippocampus (Ramsden et al., 2005; Spires et al., 2006; Holmes et al., 2016), we did not observe any signiﬁcant differences in signal intensities in time point by time point comparisons to wild-types [Fig. 3C(ii and iii)]. There were, however, subtle elevations in signal intensities in both of these regions in the rTg4510 mouse, which we investigated further. We observed increased IntensityMax values [rTg4510 rostral cortex and hippocampus, 13.1 (95% CI, 9.16 to 17.2%) and 15.0 (95% CI, 9.95 to 20.0%), respectively versus 7.43 (95% CI, 3.67 to 11.2%) and 8.57 (95% CI, 4.89 to 12.3%) in wild-type animals, P < 0.01 in both comparisons] (Table 1). Similarly, we observed reduced Time50 values [rTg4510 rostral cortex and hippocampus, 48.1 min (95% CI, 27.8 to 68.4 min) and 35.4 min (95% CI, 8.22 to 62.5 min), respectively, versus 77.1 min (95% CI, 47.9 to 106 min) and 67.0 min (95% CI, 33.8 to 100 min) in wild-type animals, P < 0.001 in both comparisons] (Table 1), indicating subtle increases in CSF-ISF exchange in these tau burdened regions. It is worth noting that these regions present with markedly less CSF ingress in the wild-type mouse brain (~7–8 fold lower), compared to other regions, which may account for the more subtle differences between animal groups observed.

In the cerebellum, which is not affected by tau pathology nor neurodegeneration (Ramsden et al., 2005), no differences were observed in intensity versus time datasets [Fig. 3C(iv)], Time50 or IntensityMax values (Table 1), between rTg4510 and wild-type animals, indicating lack of any change in CSF-ISF exchange in this region.

Reduced CSF-ISF exchange, clearance of tau, and polarization of AQP4 in the rTg4510 mouse

Based on the observed differences in CSF-ISF exchange in the rTg4510 compared to wild-type mice, we focused further on the impairment observed in contrast-enhanced magnetic resonance data, as well as clearance of tau from the brain, and AQP4 polarization (Fig. 4). Penetration eﬃciency of the MRI contrast agent in both the caudal and rostral cortex (Fig. 4A) again demonstrated the impairment of glymphatic CSF-ISF exchange in the caudal cortex of the rTg4510 mouse [penetration eﬃciency in the caudal cortex of rTg4510 mice, 0.17 (±0.05), versus 1.52 (±0.10) in the wild-type animals, P < 0.0001]
This reduction in contrast agent infiltration into the caudal cortex of rTg4510 mice was particularly evident in coronal MRI (Fig. 4B, arrow highlighting penetration in wild-type brains, arrowhead indicating lack of penetration in rTg4510 animals).

To assess whether or not such a reduction in CSF-ISF exchange also translated to a reduction in clearance of tau from the rTg4510 brain, tau containing brain homogenate was infused into either the rostral or caudal cortex of transgenic mice (Fig. 4D). CSF tau content revealed a similar pattern to contrast-enhanced magnetic resonance data. As previously noted, following infusion of tau into the cortex in wild-type animals, greater clearance was observed from the caudal as opposed to the rostral cortex (Figs 2E and 4E). Compared to non-injected controls, after rTg4510 mice receive infusion of tau into the rostral cortex, greater tau CSF concentration was observed indicative of tau parenchymal-CSF tau clearance [tau concentration in CSF following rostral cortex infusion in rTg4510 mice, 7.55 ng/ml (±0.53 ng/ml) versus 7.35 ng/ml (±0.77 ng/ml) in non-injected rTg4510 mice, P < 0.05]. However, after rTg4510 mice receive infusion of tau into the caudal cortex, no difference was observed in CSF tau concentration suggestive of compromised tau clearance (Fig. 4E). It should be noted that rTg4510 mice exhibit a far higher level of human tau in the circulating CSF, due to expression of the mutant tau transgene in the brain, and hence comparisons in these mice have been made to non-injected rTg4510 animal CSF rather than to wild-type mouse CSF data.
Table 1 Altered CSF-ISF exchange in rTg4510 mice

| Brain Region | Wild-type | rTg4510 | Effect |
|--------------|-----------|---------|--------|
| | Best-fit value | 95% CI | Best-fit value | 95% CI | Significance |
| Caudal cortex | | | | |
| Intensity\textsubscript{max} (%) | 60.17 | 54.85–65.50 | 13.00 | 6.553–19.44 | | \( P < 0.0001 \) **** |
| Time\textsubscript{50} (min) | 39.66 | 32.38–46.94 | 76.50 | 41.31–111.7 | | \( P < 0.001 \) *** |
| Rostral cortex | | | | |
| Intensity\textsubscript{max} (%) | 7.432 | 3.671–11.19 | 13.18 | 9.163–17.20 | | \( P < 0.01 \) ** |
| Time\textsubscript{50} (min) | 77.14 | 47.89–106.4 | 48.09 | 27.77–68.40 | | \( P < 0.01 \) ** |
| Hippocampus | | | | |
| Intensity\textsubscript{max} (%) | 8.571 | 4.891–12.25 | 15.00 | 9.951–20.05 | | \( P < 0.01 \) ** |
| Time\textsubscript{50} (min) | 67.04 | 33.83–100.2 | 35.35 | 8.222–62.48 | | \( P < 0.01 \) ** |
| Cerebellum | | | | |
| Intensity\textsubscript{max} (%) | 18.67 | 10.37–26.97 | 13.94 | 11.08–16.79 | | \( P > 0.05 \) |
| Time\textsubscript{50} (min) | 78.49 | 49.56–107.4 | 56.63 | 42.29–70.98 | | \( P > 0.05 \) |

Best-fit values and associated 95% CIs for Intensity\textsubscript{max} (the maximal intensity achieved in the brain region) and Time\textsubscript{50} (the time at which half maximal intensity is achieved), extracted from sigmoidal fitting of wild-type and rTg4510 MRI T1 signal intensity versus time data presented in Fig. 3, showing opposing effects in the caudal cortex compared to the rostral cortex and hippocampus. \( n = 5 \) per group. Statistical significance: *** \( P < 0.001 \), **** \( P < 0.0001 \), ** \( P < 0.01 \), * \( P < 0.05 \).

Effect of pharmacological inhibition of AQP4 on CSF-ISF exchange and clearance of tau

Based on these altered AQP4 expression and polarization profiles, the role of AQP4 in glymphatic inflow and clearance of tau was further investigated, via its pharmacological blockade, with a specific inhibitor, TGN-020 (Huber et al., 2009). In a cohort of wild-type mice, TGN-020 or vehicle were administered 15 min prior to cisternal infusion of Gd-DTPA, and serial acquisition of T1-weighted MRI for assessment of CSF-ISF exchange (Fig. 6A and B). Mice treated with TGN-020 exhibited significant reductions in magnetic resonance signal enhancement in the brain (Fig. 6C). This was clearly evident in the cortex [Fig. 6C(i)], striatum [Fig. 6C(ii)] and hippocampus [Fig. 6C(iii)], with significantly reduced magnetic resonance signal (\( P < 0.05 \)) being observed in TGN-020 treated animals from ~80 min after the start of contrast agent infusion.

To determine if pharmacological blockade of AQP4 exhibited a similar reduction in clearance of tau from the brain, wild-type mice were treated with either TGN-020 or vehicle, 15 min prior to intrastriatal infusion of tau containing brain homogenate (Fig. 6D and E). The striatum was chosen for injection of tau in these experiments given the potent reduction in contrast agent infiltration observed in the above magnetic resonance experiments, and the relatively large and homogenous nature of this subcortical brain structure. CSF was then collected from the cisterna magna, 15, 30, or 60 min later to determine the extent of clearance into CSF compartments. Reduced levels of total and phosphorylated (pS199) tau were detected in CSF following TGN-020 treatment [e.g. 15min post-striatal infusion, TGN-020 treated animal CSF total and phosphorylated (pS199) tau content, 0.09 ng/ml (±0.02 ng/ml) and 0.02 ng/ml (±0.01 ng/ml) respectively, versus 1.01 ng/ml (±0.25 ng/ml) and 0.30 ng/ml (±0.08 ng/ml) in vehicle-treated animals, \( P < 0.0001 \) in both...
Figure 3 Altered CSF-ISF exchange in rTg4510 mice. (A) Representative pseudocolour scaled sagittal (~0.5 mm lateral of bregma) images of a (A) wild-type and (B) rTg4510 mouse brain after cisterna magna infusion of Gd-DTPA, showing infiltration of contrast agent into the brain parenchyma. Scale bars = 1 mm. (C) MRI T1 signal intensity versus time data acquired from areas affected by tau pathology in the rTg4510 mouse model: the (Ci) caudal cortex, (Cii) rostral cortex and the (Ciii) hippocampus; and the (Civ) cerebellum, which is void of tau pathology in the mouse. Mean ± SEM of data and fitted curves shown. Extracted parameter of fitting displayed in Table 1. n = 5 per group. Statistical significance denoted by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.
comparisons] (Fig. 6F and G). Similar experiments were also performed in Aqp4−/− mice, where vehicle or TGN-020 was given 15 min prior to intrastriatal infusion of tau containing brain homogenate and CSF extracted 30 min later. Similar to TGN-020 treated wild-types (P  0.001), Aqp4−/− vehicle treated mice showed a reduction in CSF tau compared to vehicle-treated wild-types [Aqp4−/− mice 0.07 ng/ml (±0.01 ng/ml) versus 0.63 ng/ml (±0.13 ng/ml) in wild-type mice, P  0.001] (Fig. 6H), further suggesting that glymphatic clearance of tau depends on AQP4. In addition, when Aqp4−/− mice were treated with TGN-020, no further inhibition of tau clearance was observed [vehicle and TGN-020 treated Aqp4−/− mice CSF total tau, 0.06 ng/ml (±0.01 ng/ml) and 0.10 ng/ml (±0.02 ng/ml), respectively] (Fig. 6H), indicative of the specific nature of this agent for AQP4 and the dependence of glymphatic function on this water channel.

Together these data suggest the specific nature of TGN-020 as an AQP4 inhibitor, and the imperative nature of AQP4 function for CSF-ISF exchange and clearance of tau from the mouse brain. This suggests that the observed perturbation in AQP4 polarization observed in the caudal cortex of rTg4510 mice may be a critical factor in the impairment of glymphatic inflow, and clearance of tau from this brain region in the rTg4510 mouse.
Figure 5 AQP4 expression and polarization in rTg4510 mice. Quantification of (A) mRNA and (B) protein expression of AQP4 in the rostral and caudal cortex of wild-type and rTg4510 mice, demonstrating upregulation in rTg4510 mice compared to wild-type controls. (C) Representative example images of brain tissue from wild-type and rTg4510 mice immunohistochemically stained for AQP4. Arrows indicate examples of immunopositive blood vessels in each image, which are shown at greater magnification in insets. (D) Representative immunofluorescence images of blood vessels in the caudal cortex of (Di) wild-type, and (Dii) rTg4510 mice stained for AQP4 and CD31, illustrating placement of 4-μm axis perpendicular to blood vessels for quantification of expression across vessel cross-sections, illustrating reduced AQP4 expression surrounding blood vessels in the caudal cortex of rTg4510 mice (E). (F) Quantification of AQP4 polarization similarly demonstrated reduced polarization to blood vessels in the caudal cortex of rTg4510 mice. This is further exemplified in caudal cortex sections stained for AQP4 and GFAP, demonstrating reduced endfoot AQP4 vessel coverage in the rTg4510 caudal cortex compared to wild-type (G). n = 5–9 per group. Statistical significance denoted by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6 Effect of pharmacological inhibition of AQP4 on CSF-ISF exchange and clearance of tau. (A) Timeline and (B) schematic illustrating experiments used to determine the effects of pharmacological inhibition of AQP4 on glymphatic inflow in the mouse brain. (C) MRI T1 signal intensity versus time data acquired from the (Ci) cortex, (Cii) striatum, (Ciii) hippocampus during these experiments, demonstrating significant inhibition of glymphatic inflow. (D) Timeline and (E) schematic illustrating experiments used to determine the effects of pharmacological inhibition of AQP4 on clearance of tau from the mouse brain. (F) Total tau and (G) pTau (pS199) concentration of CSF samples extracted (continued)
Discussion

Here we demonstrate that in a tauopathy model, the cortical accumulation of tau is not solely allied to regional promoter activity, raising the question as to whether the glymphatic system may be involved in regulation of tau clearance in Alzheimer’s disease. As such, we investigated the healthy mouse brain to establish if there was a pattern of glymphatic clearance that could account for the regional nature of cortical tau deposition. We demonstrated that CSF-ISF exchange was lower in the rostral cortex, which was associated with accelerated tau deposition in Alzheimer’s disease mice. Quantifying glymphatic clearance in the rTg4510 mouse, we observed that CSF-ISF exchange and clearance of tau became impaired in the caudal cortex. In concert, we demonstrated that the level of AQP4 polarization to astrocytic endfeet was reduced in regions where glymphatic inflow and clearance of tau were impaired. Finally, we showed a marked reduction of CSF-ISF exchange and tau clearance with pharmacological inhibition of AQP4. Together these data suggest that glymphatic CSF-ISF exchange, and its role in clearance of tau from the brain, are impaired in this tau Alzheimer’s disease model, and that blocking AQP4 leads to decreased tau clearance, supporting pharmacological targeting of AQP4 for glymphatic modulation in tauopathic dementias such as Alzheimer’s disease.

Our initial finding of heterogenous tau deposition in the rTg4510 mouse cortex is counter-intuitive given the homogenous expression of the pathology-driving promoter, CaMK2α, in the mouse cortex. However, our subsequent findings of lower glymphatic inflow and clearance of tau in the rostral compared to caudal mouse cortex, suggest that CSF-ISF exchange may play a role in regional clearance, and therefore the deposition of tau in this animal model of tauopathy. The transport capacity of the glymphatic system has been shown to be driven by arterial pulsation (Iliff et al., 2013b), and therefore regional differences in CSF-ISF exchange observed here in the cortex may be attributable to discrepancies in arterial architecture and input. Correspondingly, Xiong et al. (2017) showed that what we define as the rostral cortex receives ∼30% of the arterial input of the anterior cerebral artery and ∼40% of the middle cerebral artery. Whereas the caudal aspect of the cortex receives arterial input from both of these sources (∼10% and ∼30%, respectively) as well as the posterior cerebral and superior cerebellar arteries, and the anterior choroidal artery (Xiong et al., 2017). Added to this, the hippocampus receives only ∼10% of the arterial input of the posterior cerebral and superior cerebellar arteries, and only ∼0.1% of the input from the anterior choroidal artery (Xiong et al., 2017), in line with the low level of glymphatic inflow similarly observed in this brain region. In the current study we have not addressed whether such a low level of fluid exchange in the hippocampus also translates to a low extent of tau clearance, yet these data raise the suggestion as to the susceptibility of the hippocampus, like the rostral cortex, to deposition of tau protein. As can be seen in Fig. 1, rTg4510 animals exhibiting early tau pathology in the rostral cortex (e.g. ∼3.2 months, Fig. 1C), also exhibit tau deposition in the subiculum of the hippocampus (Fig. 1, arrows), which worsens with age to affect the entire structure (∼4.6 months, Fig. 1E). If the regional nature of CSF-ISF exchange observed here in the mouse brain translates across species to the human, this would correlate with the neuropathological picture of tau pathology in Alzheimer’s disease, as these brain regions present with tau pathology in the earliest stages of disease progression (Braak and Braak, 1995).

In the cohort of rTg4510 mice examined in our study, we observed subtle increases in CSF-ISF exchange and tau clearance. We hypothesize that these effects are due to neurodegeneration as a result of NFT pathology. For example, the rostral cortex and hippocampus, which are both markedly burdened by tau pathology (Fig. 1E), present with subtle increases in fluid exchange compared to wild-types. Conversely, in the cerebellum, which is void of tau pathology (Ramsden et al., 2005), no differences were observed in contrast agent infiltration between wild-type and rTg4510 cohorts. Previously it has been observed that as glymphatic function declines with age (Kress et al., 2014), so does extracellular volume (Syková et al., 2005). We hypothesize therefore that increased extracellular volume as a result of tau-induced neurodegeneration would result in elevated magnetic resonance contrast agent inflow, as we observe here. It remains unclear, however, as to whether the subtle increase in glymphatic inflow would have any marked neurophysiological consequence in terms of elevated glymphatic clearance of toxic protein species in an already significantly degenerated scenario.

Consistent with data from others (Iliff et al., 2014), our findings suggest that tau, in the extracellular space, is a substrate for clearance via the glymphatic pathway. Furthermore recent observations have suggested that tau, using the extracellular space as a conduit, is able to propagate from neuron-to-neuron via a ‘prion’-like mechanism (Chesser et al., 2013; Ahmed et al., 2014; Medina and Avila, 2014; Clavaguera et al., 2015; Lewis and Dickson,
The functional relevance of appropriate glymphatic clearance of extracellular tau may therefore be of prime importance in neurodegenerative tauopathies, in which propagating pathology are thought to occur. An additional consideration to take is that once tau is cleared from the parenchyma into the CSF sink, the recirculating nature of CSF in the glymphatic clearance system suggests that tau-laden CSF may be re-internalized into the peri-arterial space and parenchyma (Nedergaard, 2013). In traumatic brain injury for example, a 40,000-fold increase of CSF tau is observed following injury (Zemlan et al., 2002), resulting in typical paravascular predominance of tau-immunoreactive neurofibrillary tangles (Goldstein et al., 2012). If CSF tau possesses the ability to ‘re-infect’ the brain, it raises the vital role of effective absorption methods of tau at the CSF–blood barrier and arachnoid villi, through the cervical lymphatic system, and the recently discovered meningeal lymphatics (Louveau et al., 2015, 2017), in addition to appropriate function of the glymphatic clearance system.

Part of the aquaporin family of integral membrane proteins, AQP4 is the primary facilitator of transmembrane water transport in the brain, lowering the driving forces for fluid transport across plasma membranes (Nagelhus and Ottersen, 2013; Verkman et al., 2017). Supportive of this notion that AQP4 supports and facilitates intraparenchymal fluid flow, AQP4 deletion potentiates increases in intracranial pressure (ICP) in a mouse model of hydrocephalus (Bloch et al., 2006). AQP4 is expressed highly on the astrocytic endfeet, which face the perivascular space and is hence strategically positioned to allow rapid CSF and ISF exchange. Glymphatic flow of CSF into the brain’s interstitium and its clearance out of the parenchyma, is therefore thought to be facilitated by this localized expression and polarization of AQP4 to the endfeet of astrocytes surrounding blood vessels in the brain (Mestre et al., 2018). Original data supporting this hypothesis came from the use of AQP4 null mice, in which glymphatic clearance was shown to be impaired by ~70% compared to wild-type animals, resulting in a ~55% reduction in amyloid-β clearance from the brain (Iliff et al., 2012). Despite facing controversy (Jin et al., 2016; Smith and Verkman, 2018) and concern relating to lack of reproducibility (Smith et al., 2017), several independent groups have now similarly demonstrated that astrocytic AQP4 is essential for fast glymphatic transport, using various different approaches of AQP4 gene deletion (Plog et al., 2015; Achariyar et al., 2016; Lundgaard et al., 2016; Murlidharan et al., 2016). In our current study, we have taken a different approach, and demonstrate that by pharmacologically inhibiting AQP4 function we observed a marked effect on glymphatic function; pharmacological inhibition resulted in a ~85% reduction in MRI quantified CSF-ISF exchange, and a similar reduction in tau clearance from the brain. This effect is even more striking given previous evidence of cerebral blood flow (CBF) elevation (~20%) in the mouse brain upon TGN-020 treatment (Igarashi et al., 2013), and the opposing effect this would have upon glymphatic clearance given the intrinsic link between CBF, arterial pulsatility, and CSF-ISF exchange (Iliff et al., 2013b; Bedussi et al., 2016).

Herein, our findings demonstrate the importance of AQP4 for appropriate glymphatic clearance from the brain parenchyma, alongside studies using genetic deletion approaches (Iliff et al., 2012; Plog et al., 2015; Achariyar et al., 2016; Lundgaard et al., 2016; Murlidharan et al., 2016). Our data suggest a role for AQP4-mediated clearance of tau from the brain, which therefore implies its importance in neurodegenerative tauopathies such as Alzheimer’s disease (Xu et al., 2015).

We observed here that AQP4 mRNA and protein expression levels are increased in the brains of rTg4510 mice, which is consistent with data from other degenerative Alzheimer’s disease scenarios (Yang et al., 2011; Matarin et al., 2015; Xu et al., 2015). The Nedergaard laboratory suggest, however, that in addition to its appropriate expression in the brain, AQP4 must also be suitably polarized to astrocytic endfeet, in order to facilitate appropriate CSF-ISF exchange (Kress et al., 2014). Reactive astrogliosis, though common place in degenerative Alzheimer’s disease phenotypes, is associated with increased AQP4 expression, and reduced AQP4 polarization (Iliff et al., 2014; Kress et al., 2014). Hence it is likely that reactive astrogliosis in the cortex of rTg4510 mice is responsible for the upregulations of AQP4 mRNA and protein levels observed. Yet given the phenotype of reduced polarization in such astrocytes, these upregulated expressions do not result in respective increases in AQP4 polarization, nor significantly elevated fluid exchange in the inflamed brain. Moreover, in the caudal cortex of rTg4510 mice, upregulation of AQP4 mRNA resulted in only subtle elevation in AQP4 protein, and significant reduction in both AQP4 polarization and CSF-ISF exchange. This questions the integrity of the membrane binding complex in astrocytes within this region, which facilitate AQP4 endfeet localization (Amiry-Moghaddam et al., 2004; Camassa et al., 2015). Studies from the Iliff laboratory have implicated α-synuclein, an element of the AQP4 membrane binding complex, to be vital for glymphatic clearance (Mestre et al., 2018), in that α-synuclein knockout mice, despite expressing AQP4 at normal levels (Amiry-Moghaddam et al., 2003), present with impaired glymphatic function. Further study of astrocytes in the caudal cortex of rTg4510 mice would therefore shed light on to the root cause of impaired glymphatic clearance in this model, and whether or not membrane complex elements such as α-synuclein, or their PDZ binding domains, are affected (Camassa et al., 2015) in degenerative tauopathy. To our knowledge, the data presented herein represent the first demonstration of perturbed AQP4 polarization in a tau model of Alzheimer’s disease. Taken together with similar findings in an amyloid-β model (Yang et al., 2011), in aged mice (Kress et al., 2014), and also in human Alzheimer’s disease (Zeppenfeld et al., 2016), this research points to AQP4 as a novel therapeutic target for Alzheimer’s disease.
To assess glymphatic CSF-ISF exchange in the mouse brain using MRI, we adapted a previously published protocol for measurements in the rat brain (Iliff et al., 2013a), by scaling down both the volume (80 μl in rat, 30 μl in mouse) and flow rate (1.6 μl/min in rat, 0.6 μl/min in mouse) at which intrathecal magnetic resonance contrast agent is administered. Our findings parallel patterns of glymphatic flow described in the brain using similar contrast infusion techniques in rodents (Iliff et al., 2013a; Gaberel et al., 2014). One technical challenge in the study of CSF-ISF exchange is the necessity to deliver contrast agents directly into the brain, leading to, for example, elevation of ICP brought about by the infusion itself. In the rat brain, intrathecal infusion has only been shown to increase ICP at ≥3 μl/min (Yang et al., 2013; Bedussi et al., 2016). Therefore, studies of the glymphatic system using intracisternal infusion rates of 1.6 μl/min in the rat brain are unlikely confounded by altered ICP (Iliff et al., 2013a). In our studies of the mouse brain, we scaled down this infusion rate even further to 0.6 μl/min, and hence do not anticipate confounding of measurements. Furthermore, we apply two distinct methodologies to measure clearance: MRI of glymphatic inflow, and direct parenchymal injection, and observe good consistency between these different measures. The latter method of assessment of clearance, i.e. tau injection and quantification in extracted CSF, is itself prone to a relatively high degree of variability. This may stem from numerous factors, including the accuracy of microinjection, its location in relation to CSF extraction, the efficiency and purity (lack of blood contamination) of CSF extracts, and the accuracy and sensitivity of tau detection methods. Notwithstanding, we observe good alignment of data between these two complimentary methodological approaches, which strengthens the credibility of the findings presented here.

Here we provide the first description of changes in glymphatic CSF-ISF exchange, and clearance of tau from the brain of a mouse model of tauopathy, and suggest that the decline in function observed may be capable of exacerbating, or driving accumulation of tau in the brain, and by extension, neurodegeneration in Alzheimer’s disease. Our finding of impaired AQP4 polarization in affected regions of the tauopathy brain, and the effect of pharmacological AQP4 inhibition, suggest that this water channel may present as a novel target for modulation of this pathway for therapeutic effect in Alzheimer’s disease.

Funding

This work was funded by research grants from Eli Lilly and Company, and the Engineering and Physical Sciences Research Council (EPSRC) UK (EP/N034864/1). I.H. is supported by Alzheimer’s Research UK (ARUK-RF2019A-003) and Parkinson’s UK (F-1902) fellowships. J.W. is supported by a Wellcome Trust/Royal Society Sir Henry Dale Fellowship (204624/Z/16/Z). M.F.L. receives funding from the EPSRC (EP/N034864/1); the King’s College London and UCL Comprehensive Cancer Imaging Centre CR-UK & EPSRC, in association with the MRC and DoH (England); UK Regenerative Medicine Platform Safety Hub (MRC: MR/K026739/1); Eli Lilly and Company.

Competing interests

This work was part funded by a research grant from Eli Lilly and Company, of which Z.A., A.F., S.M., T.K.M. and M.J.O’N. are/were paid members of staff.

Supplementary material

Supplementary material is available at Brain online.

References

Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol Neurodegener 2016; 11: 74.

Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 2014; 127: 667–83.

Amiry-Moghaddam M, Frydenlund DS, Ottersen OP. Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport. Neuroscience 2004; 129: 997–1008.

Amiry-Moghaddam M, Otsuka T, Hurn PD, Traystman RJ, Haug F-M, Froehner SC, et al. An α-synuclein-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc Natl Acad Sci USA 2003; 100: 2106–11.

Bedussi B, NNvd W, Jd V, Hv V, Siebes M, VanBavel E, et al. Paravascular channels, cisterns, and the subarachnoid space in the rat brain: a single compartment with preferential pathways. J Cereb Blood Flow Metab 2016; 37: 1374–85.

Bloch O, Auguste KI, Manley GT, Verkman A. Accelerated progression of Kaolin-induced hydrocephalus in aquaporin-4 deficient mice. J Cereb Blood Flow Metab 2006; 26: 1527–37.

Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271–8.

Camassa LMA, Lunde K, Hoddevik EH, Stensland M, Boldt HB, De Souza GA, et al. Mechanisms underlying AQP4 accumulation in astrocyte endfeet. Glia 2015; 63: 2073–91.

Chesser A, Pritchard S, Johnson G. Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol 2013; 4: 122.

Clavaguera F, Hench J, Goedert M, Tolnay M. Invited review: prion-like transmission and spreading of tau pathology. Neuropathol Appl Neurobiol 2015; 41: 47–58.

Gaberel T, Gakuba C, Goulay R, De Lazzarondo SM, Hanouz JL, Emery E, et al. Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRE: a new target for fibrinolysis? Stroke 2014; 45: 3092–6.

Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 2003; 60: 1495–500.
Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease. J Mol Neurosci 2001; 17: 137–45.

Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci 2017; 40: 189–210.

Goldstein LE, Fisher AM, Tagge CA, Zhang X-L, Velisek L, Sullivan JA, et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med 2012; 4: 134ra60.

Guerreiro R, Bras J. The age factor in Alzheimer’s disease. Genome Med 2015; 7: 106.

Hadjihambi A, Harrison IF, Costas-Rodrı´guez M, Vanhaecke F, Arias Guerreiro R, Mestre D, et al. Age-dependent glycemic control and neurodegeneration. Front Cell Neurosci 2014; 8: 113.

Hawkes CA, Jayakody N, Johnston DA, Bechmann I, Carare RO. Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy. Brain Pathol 2014; 24: 396–403.

Holmes HE, Colgan N, Ismail O, Ma D, Powell NM, O’Callaghan JM, et al. Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiol Aging 2016; 39: 184–94.

Holter KE, Kehlet B, Devor A, Sejnowski TJ, Dale AM, Omholt SW, et al. Impaired β-secretase activity as a cause of tauopathy (P301L). J Neurosci Res 2005; 82: 5589–94.

Huber VJ, Tsuji T, Nakada T. Identification of aquaporin 4 inhibitors using in vitro and in silico methods. Bioorg Med Chem 2009; 17: 411–7.

Igarashi H, Tsuji T, Suzuki Y, Kwee IL, Nakada T. Inhibition of aquaporin-4 significantly increases regional cerebral blood flow. Neuroreport 2013; 24: 324–8.

Iff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci 2014; 34: 16180–93.

Iff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest 2013a; 123: 1299–309.

Iff JJ, Wang M, Liao Y, Plog BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012; 4: 147ra11–ra11.

Iff JJ, Wang M, Zeppenfeld DM, Venkataraman A, Plog BA, Liao Y, et al. Cerebral arterial pulsation drives paravascular CSF–interstitial fluid exchange in the murine brain. J Neurosci 2013b; 33: 18190–9.

Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The glymphatic system: a Beginner’s Guide. Neurochem Res 2015; 1–17.

Jin B-J, Smith AJ, Verkman AS. Spatial model of convective solute transport in brain extracellular space does not support a “glymphatic” mechanism. J Gen Physiol 2016; 148: 489–501.

Kress BT, Iff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 2014; 76: 845–61.

Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 2016; 131: 27–48.

Louveau A, Plog BA, Amsta S, Altaloo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest 2017; 127: 3210–9.

Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523: 337.

Lundgaard I, Lu ML, Yang E, Peng W, Mestre H, Hitomi E, et al. Glymphatic clearance controls state-dependent changes in brain lactate concentration. J Cereb Blood Flow Metab 2016; 36: 2112–24.

Matarin M, Salih Dervis A, Yasvoina M, Cummings Damian M, Guelfi S, Liu W, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep 2015; 10: 633–44.

Medina M, Avila J. The role of extracellular Tau in the spreading of neuro fibrillary pathology. Front Cell Neurosci 2014; 8: 113.

Mestre H, Hablitz LM, Xavier ALR, Feng W, Zou W, Pu T, et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. elife 2018; 7: e40070.

Murakiharan G, Crowther A, Reardon RA, Song J, Asokan A. Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain. JCI Insight 2016; 1: e88034.

Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev 2013; 93: 1543–62.

Nedergaard M. Garbage truck of the brain. Science 2013; 340: 1529–30.

Paxinos G, Franklin K. The mouse brain in stereotaxic coordinates. 4th edn. London: Elsevier Inc.; 2013.

Peng W, Achariyar TM, Li B, Liao Y, Mestre H, Hitomi E, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer’s disease. Neurobiol Dis 2016; 93: 215–25.

Plog BA, Dashnow ML, Hitomi E, Peng W, Liao Y, Lou N, et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci 2015; 35: 518.

Ramsden M, Kottke L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillar tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005; 25: 10637–47.

Smith AJ, Verkman AS. The “glymphatic” mechanism for solute clearance in Alzheimer’s disease: game changer or unproven speculation? FASEB J 2018; 32: 543–51.

Smith AJ, Yao X, Dix JA, Jin B-J, Verkman AS. Test of the ‘glymphatic’ hypothesis demonstrates diffusive and aquaporin-4-independent solute transport in rodent brain parenchyma. elife 2017; 6: e27679.

Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, et al. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006; 168: 1598–607.

Syková E, Voieik I, Antonova T, Mazel T, Meyer-Luehmann M, Jucker M, et al. Changes in extracellular space size and geometry in APP23 transgenic mice: A model of Alzheimer’s disease. Proc Natl Acad Sci USA 2005; 102: 479–84.

Tarsa-Connaway JM, Carare RO, Osorio RS, Glodzik I, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurosci 2015; 11: 457–70.

Thane AS, Rappold PM, Fujita T, Torres A, Bekar LP, Takano T, et al. Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events elicited by cerebral edema. Proc Natl Acad Sci USA 2011; 108: 846–51.

Verkman AS, Tradrantip L, Smith AJ, Yao X. Aquaporin water channels and hydrocephalus. Pediatri Neurosurg 2017; 52: 409–16.

Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. SYMPOSIUM: clearance of Aβ from the brain in Alzheimer’s Disease: perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 2008; 18: 233–66.

Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, Smith AJ, Yao X, Dix JA, Tarasoff-Conway JM, et al. Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events elicited by cerebral edema. Proc Natl Acad Sci USA 2011; 108: 846–51.

Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolic clearance from the adult brain. Science 2013; 342: 373–7.

Xiong B, Li A, Lou Y, Chen S, Long B, Peng J, et al. Precise cerebral vascular Atlas in stereotactic coordinates of whole mouse brain. Front Neuroanat 2017; 11: 128.

Xu Z, Xiao N, Chen Y, Huang H, Marshall C, Gao J, et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits. Mol Neurodegener 2015; 10: 58.
Impaired glymphatic clearance in Alzheimer’s

Yang J, Lunde LK, Nuntagij P, Oguchi T, Camassa LMA, Nilsson LNG, et al. Loss of astrocyte polarization in the Tg-ArcSwe mouse model of Alzheimer’s disease. J Alzheimers Dis 2011; 27: 711–22.

Yang L, Kress B, Weber H, Thiyagarajan M, Wang B, Deane R, et al. Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. J Transl Med 2013; 11: 107.

Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res 2002; 947: 131–9.

Zeppenfeld DM, Simon M, Haswell J, et al. Association of perivascular localization of aquaporin-4 with cognition and alzheimer disease in aging brains. JAMA Neurol 2016; 74: 91–9.

Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid [beta]-peptide from brain: transport or metabolism. Nat Med 2000; 6: 718.